A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141934
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : April 5, 2007
Information provided by:

Brief Summary:
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and safety, AD 452 is being tested in a 3 month study. Patients enrolled in this study will already be taking methotrexate for their RA and they will remain on methotrexate throughout the study. An earlier clinical study in 98 subjects with RA on stable background therapy investigated the pharmacokinetics, safety and tolerability of AD 452 taken for one month. The drug was well tolerated and no significant drug related adverse events were reported.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: AD 452 Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 232 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.
Study Start Date : August 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male/female age 18 -75
  • RA diagnosed for at least 6 months
  • Taking methotrexate for at least 6 months
  • Must have at least 4 swollen/tender joints

Exclusion Criteria:

  • Must not be pregnant/breastfeeding
  • Must not have history of other inflammatory disorders
  • Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitus, malignant melanoma, HIV, active infection, hepatitis B/C, cardiac conduction disorders, hepatic/renal insufficiency, active depression/anxiety/psychosis/schizophrenia or convulsions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00141934

United States, Florida
Clinical Research of West Florida, Inc
Clearwater, Florida, United States, 33765
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, United States, 33334
Ocala Rheumatology Research Center
Ocala, Florida, United States, 34474
Sarasota Arthritis Research Center
Sarasota, Florida, United States, 34239
Advent Clinical Research Centers, Inc.
St. Petersburg, Florida, United States, 33703
United States, Maryland
Dept of Rheumatology, Columbia Medical Practice
Columbia, Maryland, United States, 21045
United States, New Jersey
Anderson and Collins Clinical Research, Inc.
Edison, New Jersey, United States, 08817
Station Avenue
Haddon Heights, New Jersey, United States, 08035
Atlantic Coast Research LLC
Toms River, New Jersey, United States, 08755
United States, Pennsylvania
Rheumatic Disease Associates
Willow Grove, Pennsylvania, United States, 19090
Sponsors and Collaborators
Sosei Identifier: NCT00141934     History of Changes
Other Study ID Numbers: P-AD452-022
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: April 5, 2007
Last Verified: April 2007

Keywords provided by Sosei:
Rheumatoid Arthritis
ACR20 endpoint
Tender/swollen joints
Improvement in pain
Health assessment questionnaire
Profile of mood states

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases